Can you take IGF-1 DES and Kisspeptin-10 together?

There is no specific, well-documented interaction rule for combining IGF-1 DES and Kisspeptin-10 in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, IGF-1 DES or Kisspeptin-10?

IGF-1 DES is currently research-stage and Kisspeptin-10 is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

IGF-1 DES vs Kisspeptin-10

Q: What is the difference between IGF-1 DES and Kisspeptin-10?

IGF-1 DES: IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research. Kisspeptin-10: Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

IGF-1 DES

Research-stage

IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.

Full profile

Kisspeptin-10

FDA-approved

Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.

Full profile

	IGF-1 DES	Kisspeptin-10
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1	KP-10, Metastin(112-121), KISS1R agonist
Evidence	Research-stage	FDA-approved
Dosing range	50mcg–150mcg mcg, 1–2x daily, preferably post-workout	50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion)
Administration	Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect)	Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses)
Key side effects	Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses	Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing
Cited sources	2 references	3 references

Key differences

Evidence level differs: IGF-1 DES is research-stage, while Kisspeptin-10 is fda-approved.
Administration: IGF-1 DES — Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect); Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses).
Frequency: IGF-1 DES is typically 1–2x daily, preferably post-workout; Kisspeptin-10 is 1–2x daily (pulsatile administration is important — avoid continuous infusion).
Research depth: this profile cites 2 sources for IGF-1 DES vs 3 for Kisspeptin-10.

How each works

IGF-1 DES

The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.

Kisspeptin-10

Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.

Read the full IGF-1 DES profile Read the full Kisspeptin-10 profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.